Literature DB >> 1545377

Predictability of the in vivo metabolism of verapamil from in vitro data: contribution of individual metabolic pathways and stereoselective aspects.

H K Kroemer1, H Echizen, H Heidemann, M Eichelbaum.   

Abstract

In vitro studies of drug metabolism with human liver microsomes can be performed in the early stages of drug development. Such experiments may reflect the in vivo metabolism of drugs in humans and thus allow for a prediction of drug disposition before the compound is administered to humans. We tested this hypothesis for the example of verapamil, which is a calcium channel blocker that undergoes extensive metabolism. Moreover, the drug is administered as a racemate, and stereoselective first-pass metabolism favoring the extraction of the more potent S-verapamil is observed after p.o. administration. To evaluate the in vitro metabolism, microsomes prepared from 10 human livers were incubated with both S- and R-verapamil.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1545377

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  17 in total

Review 1.  Impact of stereoselectivity on the pharmacokinetics and pharmacodynamics of antiarrhythmic drugs.

Authors:  Reza Mehvar; Dion R Brocks; Majid Vakily
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

Review 2.  Effects of the antifungal agents on oxidative drug metabolism: clinical relevance.

Authors:  K Venkatakrishnan; L L von Moltke; D J Greenblatt
Journal:  Clin Pharmacokinet       Date:  2000-02       Impact factor: 6.447

Review 3.  Bioequivalence of chiral drugs. Stereospecific versus non-stereospecific methods.

Authors:  R Mehvar; F Jamali
Journal:  Clin Pharmacokinet       Date:  1997-08       Impact factor: 6.447

4.  Enantioselective kinetics of verapamil and norverapamil in isolated perfused rat livers.

Authors:  R Mehvar; J M Reynolds; M A Robinson; J A Longstreth
Journal:  Pharm Res       Date:  1994-12       Impact factor: 4.200

5.  Chiral bioequivalence: effect of absorption rate on racemic etodolac.

Authors:  J R Boni; J M Korth-Bradley; L S Richards; S T Chiang; D R Hicks; L Z Benet
Journal:  Clin Pharmacokinet       Date:  2000-12       Impact factor: 6.447

6.  Cytochrome P450 isoforms involved in metabolism of the enantiomers of verapamil and norverapamil.

Authors:  T S Tracy; K R Korzekwa; F J Gonzalez; I W Wainer
Journal:  Br J Clin Pharmacol       Date:  1999-05       Impact factor: 4.335

7.  Gut wall metabolism of verapamil in older people: effects of rifampicin-mediated enzyme induction.

Authors:  M F Fromm; K Dilger; D Busse; H K Kroemer; M Eichelbaum; U Klotz
Journal:  Br J Clin Pharmacol       Date:  1998-03       Impact factor: 4.335

8.  Identification of P450 enzymes involved in metabolism of verapamil in humans.

Authors:  H K Kroemer; J C Gautier; P Beaune; C Henderson; C R Wolf; M Eichelbaum
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1993-09       Impact factor: 3.000

9.  Inhibitors of alprazolam metabolism in vitro: effect of serotonin-reuptake-inhibitor antidepressants, ketoconazole and quinidine.

Authors:  L L von Moltke; D J Greenblatt; M M Cotreau-Bibbo; J S Harmatz; R I Shader
Journal:  Br J Clin Pharmacol       Date:  1994-07       Impact factor: 4.335

10.  Jejunal absorption and metabolism of R/S-verapamil in humans.

Authors:  R Sandström; A Karlsson; L Knutson; H Lennernäs
Journal:  Pharm Res       Date:  1998-06       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.